Biocon' Q2FY21 revenue grew by 11% vs. our expectation of 15% due to supply chain bottleneck and lower takeoff biosimilars' business in new geographies (covid-19 lockdown). EBITDA margins (22%) decreased by 400 bps on YoY due high R&D; expenses, frorex losses and other expenses.